Name: | Enoxaparin |
---|---|
PubChem Substance ID: | 10550003 |
Description: | Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed) |
Synonyms: |
RP 54563; Enoxaparin Sodium [USAN:INN:BAN]; Lovenox; 679809-58-6; PK 10169; Clexane; Enoxaparin sodium; Sodium salt of a low-molecular weight heparin obtained by alkaline depolymerization of the benzyl ester of heparin from porcine mucosa
|
Name: | Enoxaparin |
---|---|
Name (isomeric): | DB01225 |
Drug Type: | small molecule |
Description: | Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed) |
Synonyms: |
LMWH; Low Molecular Weight Heparin
|
Brand: | Clexane, Lovenox, Lovenox HP |
Category: | Anticoagulants, Heparins, Fibrinolytic Agents |
CAS number: | 9005-49-6 |
Indication: | For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. |
---|---|
Pharmacology: |
Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3800 to 5000 daltons. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant whi...
show more » |
Mechanism of Action: |
The mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antit...
show more » |
Absorption: | Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers. |
Protein binding: | 80% bound-albumin |
Biotransformation: | Undergoes desulfation and polymerization via the liver |
Route of elimination: | Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose. |
Half Life: | 4.5 hours |
Toxicity: | Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||
---|---|---|---|---|---|---|---|
Drug interaction: |
|